title: Morphometric evaluation of nitric oxide synthase isoforms and their cytokine regulators predict pulmonary dysfunction and survival in systemic sclerosis.
abstract: Because histopathological changes in the lungs of patients with systemic sclerosis (SSc) are consistent with alveolar and vessel cell damage, we presume that this interaction can be characterized by analyzing the expression of proteins regulating nitric oxide (NO) and plasminogen activator inhibitor-1 (PAI-1) synthesis. To validate the importance of alveolar-vascular interactions and to explore the quantitative relationship between these factors and other clinical data, we studied these markers in 23 cases of SSc nonspecific interstitial pneumonia (SSc-NSIP). We used immunohistochemistry and morphometry to evaluate the amount of cells in alveolar septa and vessels staining for NO synthase (NOS) and PAI-1, and the outcomes of our study were cellular and fibrotic NSIP, pulmonary function tests, and survival time until death. General linear model analysis demonstrated that staining for septal inducible NOS (iNOS) related significantly to staining of septal cells for interleukin (IL)-4 and to septal IL-13. In univariate analysis, higher levels of septal and vascular cells staining for iNOS were associated with a smaller percentage of septal and vascular cells expressing fibroblast growth factor and myofibroblast proliferation, respectively. Multivariate Cox model analysis demonstrated that, after controlling for SSc-NSIP histological patterns, just three variables were significantly associated with survival time: septal iNOS (P=0.04), septal IL-13 (P=0.03), and septal basic fibroblast growth factor (bFGF; P=0.02). Augmented NOS, IL-13, and bFGF in SSc-NSIP histological patterns suggest a possible functional role for iNOS in SSc. In addition, the extent of iNOS, PAI-1, and IL-4 staining in alveolar septa and vessels provides a possible independent diagnostic measure for the degree of pulmonary dysfunction and fibrosis with an impact on the survival of patients with SSc.
authors.affiliation: Universidade de São Paulo, Departamento de Patologia, Faculdade de Medicina, São Paulo,SP, Brasil.
authors.forename: E R
authors.initials: ER
authors.lastname: Parra
authors.forename: A C
authors.initials: AC
authors.lastname: Aguiar Junior
authors.forename: L O
authors.initials: LO
authors.lastname: Silva
authors.forename: H S P
authors.initials: HS
authors.lastname: Souza
authors.forename: J D
authors.initials: JD
authors.lastname: Espinoza
authors.forename: V L
authors.initials: VL
authors.lastname: Capelozzi
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D018793:Interleukin-13 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D017563:Lung Diseases, Interstitial / Q000209:etiology / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D019001:Nitric Oxide Synthase / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D020033:Protein Isoforms / Q000097:blood; D012595:Scleroderma, Systemic / Q000150:complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology*
chemical_list: D015415:Biomarkers; D016207:Cytokines; D018793:Interleukin-13; D017395:Plasminogen Activator Inhibitor 1; D020033:Protein Isoforms; D015847:Interleukin-4; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II